PHASE-II STUDY OF ANGUIDINE IN ADVANCED BREAST-CANCER

  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (5) , 789-791
Abstract
A phase II evaluation of anguidine was carried out in 30 patients with advanced refractory breast cancer. A dose of 5.0 mg/m2 daily for 5 days was explored. The main toxic effects were nausea and vomiting, fever and chills, hypotension, skin erythema, somnolence, confusion and lethargy. Myelosuppression was minimal. Among these extensively pretreated patients, there was 1 partial responder and 1 additional patient who showed improvement (less than a partial response); both responses occurred in soft tissue sites.

This publication has 2 references indexed in Scilit: